Abstract: 5-methylpyrimidine oxygenases and their use in the modification of nucleic acids are described.

Abstract: 5-methylpyrimidine oxygenases and their use in the modification of nucleic acids are described.

Abstract: Methods, compositions and kits for selectively altering and detecting modified cytosine residues are provided.

Abstract: 5-methylpyrimidine oxygenases and their use in the modification of nucleic acids are described.

Abstract: Nucleic acids comprising ?-glucosaminyloxy-5-methylcytosine; compositions, kits and methods of producing the nucleic acids using a glycosyltransferase; and methods of using the nucleic acids are described.

Abstract: Compositions and systems are provided for the high efficiency quenching small water-soluble oligomers, or oligofluors, of from about 1-10 kd in size, where the oligofluors comprise multiple excimeric or exciplex forming fluorophores arranged on a scaffold, which are efficiently quenched by a quencher entity linked to the oligomer through a cleavable moiety. Fluorophores of interest include, without limitation, aromatic fluorophores such as pyrenes, e.g. benzopyrene, perylene, pyrene, etc. In some embodiments the oligofluor/quencher combination provides for a Stern-Vollmer constant (KSV) of greater than about 106 M?1, and may be greater than about 107 M?1, greater than about 108 M?1, or more. In some embodiments of the invention, the scaffold is a phosphodiester/glycoside backbone, e.g. an analog of a polynucleotide.

Abstract: Compositions and systems are provided for the high efficiency quenching small water-soluble oligomers, or oligofluors, of from about 1-10 kd in size, where the oligofluors comprise multiple excimeric or exciplex forming fluorophores arranged on a scaffold, which are efficiently quenched by a quencher entity linked to the oligomer through a cleavable moiety. Fluorophores of interest include, without limitation, aromatic fluorophores such as pyrenes, e.g. benzopyrene, perylene, pyrene, etc. In some embodiments the oligofluor/quencher combination provides for a Stern-Vollmer constant (KSV) of greater than about 106 M?1, and may be greater than about 107 M?1, greater than about 108 M?1, or more. In some embodiments of the invention, the scaffold is a phosphodiester/glycoside backbone, e.g. an analog of a polynucleotide.

Abstract: Novel peptidomimetics are provided, which mimic collagen. Molecular structures of interest include for imparting the collagen-mimicking property are each of: Gly-?[(E)CH?C]-Xaa-?[(E)CH?C]-Yaa; Gly-Xaa-?[(E)CH?C]-Yaa; Gly-Xaa-Yaa-?[(E)CH?CH]; Gly-?[(E)CH?C]-Xaa-?[(E)CH?C]-Yaa; Gly-Xaa-?(E)CH?C]-Yaa-?[(E)CH?CH]; Gly-?[(E)CH?C]-Xaa-Yaa-?[(E)CH?CH] and Gly-?[(E)CH?C]-Xaa-?[(E)CH?C]-Yaa-?[(E)CH?CH]. Xaa and Yaa each means a natural amino acid, Hyp or Flp. Amide bonds may be altered to create collagen mimics. Preferably a tripeptide polymer comprising at least about 60 (Gly-Pro-Hyp) repeating units and having molecular weight of at least about 40,000 is synthesized as a long, collagen-like material. The new synthetic collagen-like materials may have better resistance to degradation, better mechanical strength and/or better ability to fold than natural collagen.